The North American-AIDS Cohort Collaboration on Research and Design (NA-ACCORD) began in 2006 as the representative of Region 1 of the leDEA initiative. The 22 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV/AIDS cohorts within North America. Over 100 sites in the US and Canada contribute data collected from over 100,000 HIV-infected and 150,000 HIV-uninfected participants. During the last 4 years, we established a strong collaborative infrastructure that capitalizes on the talents and expertise of a multi-disciplinary group of investigators that span basic science, clinical research, epidemiology, data informatics and biostatistics. We have been highly productive in addressing our original Aims and expanding our scientific focus to several areas of contemporary importance in HIV in North America. Our collaboration is well-positioned to successfully answer the key questions in practice today. We have three broadly-defined aims for the next funding cycle:
Aim 1 : Determine the clinical epidemiology of HIV infection in North America, with a focus on aging and the incidence and determinants of non-AIDS co-morbidities.
Aim 2 : Provide unique data on current and evolving trends, outcomes and comparative effectiveness of treatment of HIV infection in North America, with a focus on the timing of presentation for HIV care and the initial use of ART, determinants of long-term viral suppression, immune recovery, and clinical disease progression, the impact of hepatitis C co-infection, and the development of resistance.
Aim 3 : Capitalize on our large sample size to quantify and identify factors associated with important rare events and support translational research. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to provide definitive answers to these issues of contemporary relevance in the U.S. and Canada. In addition, we will expand our collaboration with other leDEA regions to both inform future experience in resource-limited regions as the treatment of the epidemics mature, and to identify and understand differences in treatment, outcomes and prognostic factors that might inform future research and clinical care globally.

Public Health Relevance

The NA-ACCORD is the most comprehensive collaboration of HIV cohorts that exists within North America. Its large sample size, the comprehensiveness and quality of its data, combined with the expert use of state- of-the-art statistical methods will allow us to provide answers to critical questions of contemporary importance for the care of HIV-infected individuals in the U.S. and Canada.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069918-07
Application #
8298141
Study Section
Special Emphasis Panel (ZAI1-BB-A (M2))
Program Officer
Zimand, Lori B
Project Start
2006-07-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
7
Fiscal Year
2012
Total Cost
$2,166,017
Indirect Cost
$295,255
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Mayor, Angel M; Santiago-Rodriguez, Eduardo J; Rios-Olivares, Eddy et al. (2016) Malignancies Trends in a Hispanic Cohort of HIV Persons in Puerto Rico before and after cART. Int J Cancer Res 12:92-100
Rebeiro, Peter F; Gange, Stephen J; Horberg, Michael A et al. (2016) Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One 11:e0146119
Cesar, Carina; Koethe, John R; Giganti, Mark J et al. (2016) Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America. J Int AIDS Soc 19:20684
Rachlis, Beth; Karwa, Rakhi; Chema, Celia et al. (2016) Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf 39:959-76
Buchacz, Kate; Lau, Bryan; Jing, Yuezhou et al. (2016) Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 214:862-72
Santiago-Rodríguez, Eduardo J; Mayor, Angel M; Fernández-Santos, Diana M et al. (2016) Profile of HIV-Infected Hispanics with Pancytopenia. Int J Environ Res Public Health 13:ijerph13010038
Geng, Elvin H; Odeny, Thomas A; Lyamuya, Rita et al. (2016) Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. Clin Infect Dis 62:935-44
Garner, Will; White, Kirsten; Szwarcberg, Javier et al. (2016) Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials. Clin Infect Dis 62:929-34
Althoff, Keri N; Rebeiro, Peter F; Hanna, David B et al. (2016) A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts. J Int AIDS Soc 19:20707
Klein, Marina B; Althoff, Keri N; Jing, Yuezhou et al. (2016) Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis 63:1160-1167

Showing the most recent 10 out of 85 publications